Background: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein variant with atherogenic, thrombogenic, and pro-inflammatory properties that may have numerous pathologic effects, including dyslipidemia. Screening for Lp(a) is clinically significant, due to its causal role in atherosclerotic cardiovascular disease (ASCVD). Among clinicians, however, there remains a general lack of both clinical awareness of Lp(a) and adequate tools to track Lp(a) testing in patients.
View Article and Find Full Text PDFMeasurement of cortisol in fish scales is attracting considerable attention as a non-invasive indicator of chronic stress in wild populations. For many fish species of management and conservation interest, extensive scale collections exist that could provide extended records of individual stress responses, by combining cortisol measurements with life history information. However, it is not yet known how well cortisol is preserved in the scale during storage.
View Article and Find Full Text PDFListeners are sensitive to interaural time differences carried in the envelope of high-frequency sounds (ITDENV), but the salience of this cue depends on certain properties of the envelope and, in particular, on the presence/depth of amplitude modulation (AM) in the envelope. This study tested the hypothesis that individuals with sensorineural hearing loss, who show enhanced sensitivity to AM under certain conditions, would also show superior ITDENV sensitivity under those conditions. The second hypothesis was that variations in ITDENV sensitivity across individuals can be related to variations in sensitivity to AM.
View Article and Find Full Text PDFObjective: Few studies have addressed medication adherence in adolescents and young adults (AYAs) with bipolar disorder (BD). This 6-month prospective randomized-controlled trial (RCT) tested customized adherence enhancement for adolescents and young adults (CAE-AYA), a behavioral intervention for AYAs versus enhanced treatment as usual (ETAU).
Methods: Inclusion criteria were AYAs age 13-21 with BD type I or II with suboptimal adherence defined as missing ≥20% of medications.